66,475 Doximity, Inc. $DOCS Shares Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP increased its stake in Doximity, Inc. (NYSE:DOCS) by 17,401.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 66,857 shares of the company’s stock after purchasing an additional 66,475 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Doximity were worth $1,773,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Carmignac Gestion boosted its position in Doximity by 127.8% during the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after purchasing an additional 2,418,971 shares during the period. Renaissance Technologies LLC grew its stake in Doximity by 29.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after buying an additional 694,300 shares during the last quarter. Wellington Management Group LLP lifted its position in Doximity by 24.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after acquiring an additional 621,464 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Doximity during the third quarter valued at about $28,858,000. Finally, Bank of America Corp DE grew its position in shares of Doximity by 31.8% in the first quarter. Bank of America Corp DE now owns 1,142,530 shares of the company’s stock valued at $26,621,000 after purchasing an additional 275,650 shares during the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Key Doximity News

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Analyst Upgrades and Downgrades

DOCS has been the subject of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $41.00 price objective on shares of Doximity in a research report on Friday, November 6th. Freedom Capital lowered Doximity from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Barclays increased their price objective on Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a research report on Friday, August 21st. Stifel Nicolaus set a $27.00 price objective on shares of Doximity in a research note on Tuesday, September 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $47.00 target price (up from $42.00) on shares of Doximity in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $30.45.

Insider Transactions at Doximity

In other news, Director Kira Wampler sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $32.89, for a total transaction of $65,780.00. Following the sale, the director directly owned 27,923 shares in the company, valued at approximately $918,387.47. The trade was a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Timothy Cabral sold 10,721 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $35.00, for a total value of $375,235.00. Following the completion of the transaction, the director owned 8,084 shares of the company’s stock, valued at $282,940. The trade was a 57.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 24,471 shares of company stock valued at $761,545. Company insiders own 31.80% of the company’s stock.

Doximity Stock Performance

NYSE DOCS opened at $32.45 on Wednesday. Doximity, Inc. has a twelve month low of $17.15 and a twelve month high of $54.04. The stock has a market cap of $5.78 billion, a PE ratio of 42.69, a PEG ratio of 34.25 and a beta of 1.29. The firm has a 50-day simple moving average of $29.33 and a 200 day simple moving average of $25.43.

Doximity (NYSE:DOCS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.17. Doximity had a return on equity of 15.80% and a net margin of 21.12%. The firm had revenue of $174.54 million for the quarter. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The company’s revenue was up 3.6% on a year-over-year basis. Research analysts forecast that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

About Doximity

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.